Clinical trial · Observational
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
Gastrointestinal Motility in Patients With Neuroendocrine Tumors-Effects of Sandostatin LAR
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects. For this we will use radio-opaque markers and the newly developed Motility Tracking System (MTS). Hypothesis: Patients with NET and carcinoid syndrome have decreased GITT, gastric emptying and small bowel transit time and an increase in phase III MMC activity compared to healthy subjects. Treatment with somatostatin analogues increase transit times and decrease phase III MMC activity and improves the clinical symptoms.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumor | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Tracking System (MTS) and radio-opaque markers | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with NET and diarrhea.
- interventionNames
- Device: Magnetic Tracking System (MTS) and radio-opaque markers
Primary outcomes (1)
- measure
- Gastrointestinal transit time in NET patients
- timeFrame
- End of the study
Secondary outcomes (4)
- measure
- Gastric emptying in NET patients
- timeFrame
- End of the study
- measure
- Small intestinal transit time
- timeFrame
- End of the study
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * NET confirmed by histology * Diarrhea, (at least 3 loose or watery bowel movements per day) as part of carcinoid syndrome. * Newly referred patients without previous somatostatin analogue treatment or * NET patients who are pausing somatostatin analogue treatment due to other treatment or examination. Exclusion Criteria: * Subjects unable to understand the information * Severe diabetes with late complications or known metabolic disorder * Inflammatory bowel disease * Known clinically significant stenosis of the bowel * Bile acid malabsorption due to intestinal surgery * Small bowl bacterial overgrowth
References
Publications (0)
Data not yet available